197 related articles for article (PubMed ID: 38459052)
1. Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma.
Liu M; Bertolazzi G; Sridhar S; Lee RX; Jaynes P; Mulder K; Syn N; Hoppe MM; Fan S; Peng Y; Thng J; Chua R; Jayalakshmi ; Batumalai Y; De Mel S; Poon L; Chan EHL; Lee J; Hue SS; Chang ST; Chuang SS; Chandy KG; Ye X; Pan-Hammarström Q; Ginhoux F; Chee YL; Ng SB; Tripodo C; Jeyasekharan AD
Nat Commun; 2024 Mar; 15(1):2113. PubMed ID: 38459052
[TBL] [Abstract][Full Text] [Related]
2. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
3. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
4. Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.
Sangaletti S; Iannelli F; Zanardi F; Cancila V; Portararo P; Botti L; Vacca D; Chiodoni C; Di Napoli A; Valenti C; Rizzello C; Vegliante MC; Pisati F; Gulino A; Ponzoni M; Colombo MP; Tripodo C
EBioMedicine; 2020 Nov; 61():103055. PubMed ID: 33096480
[TBL] [Abstract][Full Text] [Related]
5. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.
Li X; Xu-Monette ZY; Yi S; Dabaja BS; Manyam GC; Westin J; Fowler N; Miranda RN; Zhang M; Ferry JA; Medeiros LJ; Harris NL; Young KH
Am J Surg Pathol; 2017 Oct; 41(10):1309-1321. PubMed ID: 28817403
[TBL] [Abstract][Full Text] [Related]
6. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
7. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Xu-Monette ZY; Dabaja BS; Wang X; Tu M; Manyam GC; Tzankov A; Xia Y; Zhang L; Sun R; Visco C; Dybkaer K; Yin L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Zhao X; Winter JN; Piris MA; McDonnell TJ; Miranda RN; Li Y; Medeiros LJ; Young KH
Mod Pathol; 2015 Dec; 28(12):1555-73. PubMed ID: 26541272
[TBL] [Abstract][Full Text] [Related]
8. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma.
Steen CB; Luca BA; Esfahani MS; Azizi A; Sworder BJ; Nabet BY; Kurtz DM; Liu CL; Khameneh F; Advani RH; Natkunam Y; Myklebust JH; Diehn M; Gentles AJ; Newman AM; Alizadeh AA
Cancer Cell; 2021 Oct; 39(10):1422-1437.e10. PubMed ID: 34597589
[TBL] [Abstract][Full Text] [Related]
9. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
10. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
11. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
Front Immunol; 2021; 12():732006. PubMed ID: 34745101
[TBL] [Abstract][Full Text] [Related]
12. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
13. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
[TBL] [Abstract][Full Text] [Related]
14. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.
Keane C; Tobin J; Gunawardana J; Francis S; Gifford G; Gabrielli S; Gill A; Stevenson W; Talaulikar D; Gould C; Jain S; Birch S; Hertzberg M; Gandhi MK
Eur J Haematol; 2019 Sep; 103(3):200-207. PubMed ID: 31211907
[TBL] [Abstract][Full Text] [Related]
15. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.
Ciavarella S; Vegliante MC; Fabbri M; De Summa S; Melle F; Motta G; De Iuliis V; Opinto G; Enjuanes A; Rega S; Gulino A; Agostinelli C; Scattone A; Tommasi S; Mangia A; Mele F; Simone G; Zito AF; Ingravallo G; Vitolo U; Chiappella A; Tarella C; Gianni AM; Rambaldi A; Zinzani PL; Casadei B; Derenzini E; Loseto G; Pileri A; Tabanelli V; Fiori S; Rivas-Delgado A; López-Guillermo A; Venesio T; Sapino A; Campo E; Tripodo C; Guarini A; Pileri SA
Ann Oncol; 2018 Dec; 29(12):2363-2370. PubMed ID: 30307529
[TBL] [Abstract][Full Text] [Related]
16. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
17. Pseudotemporal ordering of spatial lymphoid tissue microenvironment profiles trails Unclassified DLBCL at the periphery of the follicle.
Tripodo C; Bertolazzi G; Cancila V; Morello G; Iannitto E
Front Immunol; 2023; 14():1207959. PubMed ID: 37680642
[TBL] [Abstract][Full Text] [Related]
18. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
[TBL] [Abstract][Full Text] [Related]
19. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
Bedekovics T; Hussain S; Feldman AL; Galardy PJ
Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
[TBL] [Abstract][Full Text] [Related]
20. A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL.
Miyawaki K; Kato K; Sugio T; Sasaki K; Miyoshi H; Semba Y; Kikushige Y; Mori Y; Kunisaki Y; Iwasaki H; Miyamoto T; Kuo FC; Aster JC; Ohshima K; Maeda T; Akashi K
Blood Adv; 2022 Apr; 6(7):2388-2402. PubMed ID: 34638128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
